Thirdly, increased myostatin levels are involved with decreased muscle mass, which is a risk factor in the fibrosis of NAFLD by activating the fibrogenic hepatic stellate cells. Here, MSTN is linked to metabolic dysfunction-associated steatotic liver disease.